pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 25·1 min read
save

Upcoming Q2 earnings from Moderna, AstraZeneca, GSK and others highlighted in weekly pharma preview

Jul 25, 2026·read at Endpoints ↗EarningsNeutral

The Endpoints Weekly newsletter signals a busy earnings week for major pharmaceutical companies, with Q2 results slated from Moderna, AstraZeneca, GSK, Bristol Myers Squibb and several others.

It also mentions that AI firm Anthropic is outlining plans to expand into the life‑science arena, though specific initiatives are not detailed.

The brief further references remarks from the Novartis chief executive regarding partnership opportunities and market activity in China.

Readers are encouraged to subscribe for full access to the articles and to receive future newsletters directly.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Anthropic’s life science plans; Novartis CEO on China deals; and more”

read at Endpoints ↗
86 words · retrieved Jul 25
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA2BRISTOL2BRISTOL MYERS SQUIBB2BRISTOL MYERS SQUIBB CO2NOVARTIS2

related stories

  • 2d agoNovartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsBioSpace
  • 3d agoSTAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and moreSTAT
  • Aug 20Chutes & Ladders—Neumora shuffles leadership ahead of INDFierce Biotech
  • Aug 18AstraZeneca scores in lung cancer; Sandoz inks a China dealBioPharma Dive
  • Aug 54 potential biotech M&A targets, plus a pretty sure bet from J&JBioSpace